Literature DB >> 20011349

Medical treatment of irritable bowel syndrome.

Jason Reina1, James W Smith.   

Abstract

The identification, diagnosis, and treatment of irritable bowel syndrome (IBS) have a tremendous impact on the large number of patients with this syndrome and on physicians representing a wide variety of general and specialty practices. There are well-established diagnostic criteria and algorithms for the initial evaluation of patients presenting with the symptoms of IBS. The symptoms can be targeted for therapy with a variety of pharmaceutical and nonpharmaceutical agents. Therapy should be individualized for the patient, and the cornerstone for any effective treatment strategy should be a solid patient-physician relationship. Medications released in the past several years are based on the understanding of serotonin receptors in the gut and their role in the pathogenesis of IBS.

Entities:  

Keywords:  Irritable bowel syndrome; alosetron; functional gastrointestinal disease; tegaserod

Year:  2005        PMID: 20011349      PMCID: PMC2780138          DOI: 10.1055/s-2005-870891

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  25 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

Review 2.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 3.  Systematic review on the management of irritable bowel syndrome in North America.

Authors:  Lawrence J Brandt; David Bjorkman; M Brian Fennerty; G Richard Locke; Kevin Olden; Walter Peterson; Eamonn Quigley; Philip Schoenfeld; Marvin Schuster; Nicholas Talley
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

4.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

5.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 6.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

7.  Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care.

Authors:  D S Sanders; M J Carter; D P Hurlstone; A Pearce; A M Ward; M E McAlindon; A J Lobo
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

Review 8.  Pharmacologic therapy for the irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

9.  The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.

Authors:  D M Owens; D K Nelson; N J Talley
Journal:  Ann Intern Med       Date:  1995-01-15       Impact factor: 25.391

10.  Prognosis in the irritable bowel syndrome: a 5-year prospective study.

Authors:  R F Harvey; E C Mauad; A M Brown
Journal:  Lancet       Date:  1987-04-25       Impact factor: 79.321

View more
  1 in total

1.  Peer reviewed publications in 2005.

Authors: 
Journal:  Ochsner J       Date:  2006
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.